Zecotek Receives US$1.5 Million Order for its Patented LFS Scintillation Crystals Through Hamamatsu Photonics Partnership

Singapore, November 19, 2013 – Zecotek Photonics Inc. (TSX-V: ZMS; OTCPK: ZMSPF; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that its wholly owned subsidiary Zecotek Imaging Systems Pte. Ltd. has received a US$1,500,000 order for its patented Lutetium Fine Silicate (LFS) scintillation crystals from its strategic partner Hamamatsu Photonics (Tokyo: 6965) of Japan. This second order of LFS scintillation crystals is generated to be used by a third party OEM of positron emission tomography (PET) medical scanning devices.

“Hamamatsu is actively marketing Zecotek’s patented LFS scintillation crystals,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “PET manufacturers are recognizing the cost/performance/IP advantages of using the LFS scintillation crystal. I am very pleased with the efforts of our strategic partner Hamamatsu. The LFS technology was well covered at the recent Nuclear Science Symposium and IEEE conference in Seoul, Korea and in front of thousands of Hamamatsu’s customers at the November Photon fair in Japan. Our joint imaging projects are well on their way.”

On July 16, 2013 Zecotek and Hamamatsu announced a strategic partnership to commercialize existing imaging technologies and to collaborate on the upgrade and manufacture of photo detectors, integrated detector modules and associated electronics and data acquisition modules for the imaging markets at large. Hamamatsu is the world’s leading supplier of optoelectronics components including photo multiplier tubes and photo-diodes used in positron emission tomography (PET) medical scanners, the European Organization for Nuclear Research (CERN) projects and other industrial and scientific applications.

Zecotek’s patented (US patent No. 7,132,060) LFS series of scintillation crystals are known for their high light yields and ultra-fast decay times which allow for faster and higher-resolution operation of medical and industrial imaging devices including PET medical scanners. Zecotek’s line of LFS crystals also cover a wide range of emission wavelengths which can be tailored to match the spectral sensitivity of various photo detectors including the solid-state MAPD photo detector arrays.

The LFS scintillation crystals are manufactured under contract by the Beijing Opto-Electronics Technology Company (BOET), a subsidiary of North-China Research Institute of Electronics-Optics and an industry leader in growing, cutting, polishing and large scale production of scintillation crystals grown by the Czochralski method. Zecotek’s manufacturing process permits the growth of large-diameter boules with uniform properties and without cracking (a problem with many competing scintillation materials), resulting in high element output and lower unit costs.

– 30 –

About Hamamatsu Photonics K.K.Hamamatsu Photonics K.K. (Japan) is a leading manufacturer of devices for the generation and measurement of infrared, visible, and ultraviolet light. These devices include photomultiplier tubes, scientific light sources, opto-semiconductors, cameras, and specialized imaging systems. Hamamatsu Photonics is dedicated to the advancement of photonics through extensive research. This corporate philosophy results in state-of-the-art products which are used throughout the world in scientific, industrial, and commercial applications.

About Zecotek Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Laser Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances and joint ventures with leading industry partners such as the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), and National NanoFab Center (South Korea). For more information visit Zecotek Photonics, follow @zecotek on Twitter and “like” us in Facebook.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website atZecotek Photonics.